Friday, 5 November 2010, 2:31 pm
Press Release: ME Society
Leading World Expert in Myalgic Encephalopathy/ Chronic Fatigue
Syndrome to visit New Zealand
Professor Nancy Klimas will be visiting New Zealand in late November,
at the invitation of Associated New Zealand ME Society (ANZMES), to
update the medical community on recent developments in the research,
diagnosis, management and treatment of patients with ME/CFS, and the
ongoing investigation into the possible links with xenotropic murine
leukemia virusrelated virus (XMRV).
Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a
debilitating long-term disease that can affect anyone. In New Zealand,
it is estimated that there are around 20,000 sufferers. It is thought
to afflict around 150,000 in the UK, and over one million in the US.
Nancy Klimas is a professor of Medicine, Psychology, Microbiology and
Immunology at the University of Miami School of Medicine. She leads a
multidisciplinary research team representing the fields of immunology,
autonomic medicine, neuroendrocrinology, behavioural psychology,
rheumatology, nutrition and exercise physiology.
Prof Klimas is also director of Research for the Clinical AIDS/HIV
Research at the Miami Veterans Affairs Medical Centre.
Over the week of 21-30 November Prof Klimas will be lecturing in
Auckland, Whangarei, Hamilton, Rotorua, Tauranga, Wellington and
Dunedin. Recent investigations by the Whittemore-Peterson Institute
have been verified by independent studies performed by the National
Institutes of Health (NIH) and the Food and Drug Administration (FDA)
confirming the strong association between a family of murine leukemia
viruses (MLV), that includes XMRV, and ME/CFS.
Although this is at the early stages of investigation it does show
that ME/CFS is a real physical illness and patients need long-term
medical support and assistance from others.
There is currently no cure for the illness and there are difficulties
in making a clear diagnosis of the condition. The study by
Whittemore-Peterson Institute, NIH and the FDA may lead to the
development of both a diagnostic tool and a treatment, potentially
using medications already in use today for other conditions.